Dear Investor,
Join us for an invitation only investor dinner, featuring ARC Medical, at The Capital Grille on Thursday, October 16th, 2025.
ARC is significantly improving surgical patient recovery by preventing internal adhesions, the most common surgical complication.
Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.
Event Details:
📍 The Capital Grille,
8038 - Rockefeller Center,
120 W 51st St.
New York, NY 10020
🗓 October 16, 2025 | 5:30 PM EDT
Why Attend?
Meet ARC’s leadership team and learn how their liquid devices, JOCOAT™ and IPCOAT™, are transformative breakthroughs for surgical patients’ recovery, care and experience in knee, shoulder, gynecological and abdominal surgeries.
Connect with fellow sophisticated healthcare investors in a private setting.
Why ARC Medical?
Large Unmet Medical Needs and Markets : Surgical adhesions cause chronic pain and suffering, immobility, and infertility – with 11 million surgery patients yearly and a total addressable market of $11 billion annually.
Compelling Efficacy and Safety Clinical Data : for the company’s JOCOAT™ in orthopedic knee and shoulder surgery patients (N=17) and IPCOAT™ in a gynecological and abdominal safety clinical trial (N=76).
Strong Patents Provide Exclusivity : ARC has 5 composition of matter patents granted in each of the US and Japan and additional patents in other key territories that provide exclusivity for the company’s JOCOAT™ and IPCOAT™ through 2039 and beyond.
Experienced Leadership Team : has “been there, done that” including designing and developing a Boston Scientific partnered stent that resulted in first year sales of $2 billion; has relevant experience at J&J, Stryker, Smith+Nephew, Amgen and Moderna; and designed and ran the clinical trials resulting in the approvals and commercialization of 3 previous generation anti-surgical adhesion devices.
Momentum and Near-Term Milestones:
1. ARC’s JOCOAT™ clinical trial in knee ACL repair surgery patients is underway (N=70).
2. ARC is initiating its IPCOAT™ clinical trial in gynecological endometriosis surgery patients (N=21).
3. Topline data from both clinical trials are expected in 2026.
4. Initial approvals and sales are expected for JOCOAT™ and IPCOAT™ in 2027 in select territories including Germany, Kingdom of Saudi Arabia, United Arab Emirates, Australia and Canada.
5. Both clinical trials serve as pilot studies for the US.
What is the Investment Opportunity?
Raising $5M : ARC is now raising $5M in equity at a pre-money valuation of $45M. Use of proceeds from the $5M financing include providing 2+ years of runway, completing a partnership with a large Japanese company for Japan (currently negotiating the term sheet), and increasing the number of patients in the 2 clinical trials outlined below.
Raised to Date : ARC has raised $21M in equity and an additional $18M in non-dilutive revenues and grants. This funding has taken the company to run outside of US pivotal clinical trials, with anticipated near term clinical milestones and near term partnering announcements.
Potential $ Billion Exit : representing a 20X return based on comparable companies in the wound healing arena.
This event is exclusively limited to invited family offices, accredited investors and financial advisors.
Request investor materials by contacting: Skylar Rallison at srallison@opus8.com
Thanks much and all the best,
The Opus8 Team